High human equilibrative nucleoside transporter 1(hENT1)-expression has shown a survival benefit in pancreatic cancer patients treated with gemcitabine in several studies.The aim of this systematic review was to summa...High human equilibrative nucleoside transporter 1(hENT1)-expression has shown a survival benefit in pancreatic cancer patients treated with gemcitabine in several studies.The aim of this systematic review was to summarize the results and try to assess the predictive value of hENT1 for determining gemcitabine outcome in pancreatic cancer.Relevant articles were obtained from PubMed,Embase and Cochrane databases.Studies evaluating hENT1-expression in pancreatic tumor cells from patients treated with gemcitabine were selected.Outcome measures were overall survival,disease-free survival(DFS),toxicity and response rate.The database searches identified 10 studies that met the eligibility criteria,and a total of 855 patients were included.Nine of 10 studies showed a statistically significant longer overall survival in univariate analyses in patients with high hENT1-expression compared to those with low expression.In the 7 studies that reported DFS as an outcome measure,6 had statistically longer DFS in the high hENT1 groups.Both toxicity and response rate were reported in only 2 articles and it was therefore hard to draw any major conclusions.This review provides evidence that hENT1 is a predictive marker for pancreatic cancer patients treated with gemcitabine.Some limitations of the review have to be taken into consideration,the majority of the included studies had a retrospective design,and there was no standardized scoring protocol for hENT1-expression.展开更多
目的探讨hENT1在生发中心B细胞(germinal center B cell-like,GCB)型与非GCB(non-GCB)型弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)中的表达及意义。方法采用免疫组化PV 6000两步法检测CD10、BCL-6、MUM1蛋白在DLBCL的...目的探讨hENT1在生发中心B细胞(germinal center B cell-like,GCB)型与非GCB(non-GCB)型弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)中的表达及意义。方法采用免疫组化PV 6000两步法检测CD10、BCL-6、MUM1蛋白在DLBCL的表达并对DLBCL进行亚型分类,同时检测hENT1蛋白的表达,探讨免疫组化染色结果和临床病理参数及预后的关系。结果 (1)hENT1蛋白在DLBCL的GCB及non-GCB亚型中表达差异有显著性(P=0.031,P<0.05)。(2)hENT1的表达与患者性别、年龄、部位、LDH高低、Ann Arbor分期、有无B症状的差异均无统计学意义。(3)对76例DLBCL患者进行生存分析,中位随访时间21个月。Log-rank检验GCB/non-GCB组累计生存率差异有统计学意义(P=0.010)。结论 DLBCL中non-GCB型患者比例较大,预后差。在治疗过程中,检测hENT1的表达为能否使用核苷类药物提供依据。展开更多
Objective:To investigate the expression of hENT1 and ERCCl genes in tumor tissues non-small cell lung cancer(NSCLC).Methods:Fresh non-small lung cancer specimens were transplanted into nude mice.Twenty mice were rando...Objective:To investigate the expression of hENT1 and ERCCl genes in tumor tissues non-small cell lung cancer(NSCLC).Methods:Fresh non-small lung cancer specimens were transplanted into nude mice.Twenty mice were randomized into two groups:experimental group receiving gemeitabine plus cisplatin and control group receiving 0.9%physiological saline.The expressions of hENTi and ERCC1 mRNA in tumor tissue were detccted by real-time fluorescent quantitative PCR.The volume of tumor,the weight of nude mice and tumor volume were respectively measured and calculated 2-3 times per week.Tissue samples were collected from NSCLC mice treated with gemeitabine plus carboplatin.Results:The histological examination showed that many tumor cells were well preserved in nude mice.The rate of transplanted tumor cells was 86.7%.The concomitant treatment study showed that the rate of TV,RTV,T/C in GEM + DDP group was the lowest.LBP + DOC,DDP + DOC obviously influenced the body weight.Compared with NS group,DDP group,GEM group,the survival period and the level of hENTl of DDP+GEM group increased obviously,the level of ERCC1 decreased significantly(P【0.05).Conclusions:The expression of hENT1 and ERCC1 genes in tumor tissues were closely correlated with the response to chemotherapy and prognosis of patients with NSCLC treated with gemeitabine plus cisplatin.展开更多
Human immunodeficiency virus(HIV)is the primary infectious agent of acquired immunodeficiency syndrome(AIDS),and non-nucleoside reverse transcriptase inhibitors(NNRTIs)are the cornerstone of HIV treatment.In the last ...Human immunodeficiency virus(HIV)is the primary infectious agent of acquired immunodeficiency syndrome(AIDS),and non-nucleoside reverse transcriptase inhibitors(NNRTIs)are the cornerstone of HIV treatment.In the last 20 years,our medicinal chemistry group has made great strides in developing several distinct novel NNRTIs,including 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine(HEPT),thio-dihydro-alkoxy-benzyl-oxopyrimidine(S-DABO),diaryltriazine(DATA),diarylpyrimidine(DAPY)analogues,and their hybrid derivatives.Application of integrated modern medicinal strategies,including structure-based drug design,fragment-based optimization,scaffold/fragment hopping,molecular/fragment hybridization,and bioisosterism,led to the development of several highly potent analogues for further evaluations.In this paper,we review the development of NNRTIs in the last two decades using the above optimization strategies,including their structure-activity relationships,molecular modeling,and their binding modes with HIV-1 reverse transcriptase(RT).Future directions and perspectives on the design and associated challenges are also discussed.展开更多
Equilibrative nucleoside transporters （ENTs）, which facilitate cross-membrane transport of nucleosides and nucleoside-derived drugs, play an important role in the salvage pathways of nucleotide synthesis, cancer che...Equilibrative nucleoside transporters （ENTs）, which facilitate cross-membrane transport of nucleosides and nucleoside-derived drugs, play an important role in the salvage pathways of nucleotide synthesis, cancer chemotherapy, and treatment for virus infections. Functional characterization of ENTs at the molecular level remains technically challenging and hence scant. In this study, we report successful purification and bio- chemical characterization of human equilibrative nucle- oside transporter 1 （hENT1） in vitro. The HEK293F- derived, recombinant hENT1 is homogenous and func- tionally active in proteoliposome-based counter flow assays, hENT1 transports the substrate adenosine with a Km of 215 ＋ 34 pmol/L and a Vmax of 578 ＋ 23.4 nmol mg-1 min-1. Adenosine uptake by hENT1 is competi- tively inhibited by nitrobenzylmercaptopurine ribonu- cleoside （NBMPR）, nucleosides, deoxynucleosides, and nucleoside-derived anti-cancer and anti-viral drugs. Binding of hENT1 to adenosine, deoxyadenosine, and adenine by isothermal titration calorimetry is in general agreement with results of the competitive inhibition assays. These results validate hENT1 as a bona fide target for potential drug target and serve as a useful basis for future biophysical and structural studies.展开更多
Aim:Because mutations of splicing factor 3B subunit-1(SF3B1)have been identified in 4%of pancreatic ductal adenocarcinoma(PDAC)patients,we investigated the activity of new potential inhibitors of SF3B1 in combination ...Aim:Because mutations of splicing factor 3B subunit-1(SF3B1)have been identified in 4%of pancreatic ductal adenocarcinoma(PDAC)patients,we investigated the activity of new potential inhibitors of SF3B1 in combination with gemcitabine,one of the standard drugs,in PDAC cell lines.Methods:One imidazo[2,1-b][1,3,4]thiadiazole derivative(IS1)and three indole derivatives(IS2,IS3 and IS4),selected by virtual screening from an in-house library,were evaluated by the sulforhodamine-B and wound healing assay for their cytotoxic and antimigratory activity in the PDAC cells SUIT-2,Hs766t and Panc05.04,the latter harbouring the SF3B1 mutations.The effects on the splicing pattern of proto-oncogene recepteur d’origine nantais(RON)and the gemcitabine transporter human equilibrative nucleoside transporter-1(hENT1)were assessed by PCR,while the ability to reduce tumour volume was tested in spheroids of primary PDAC cells.Results:The potential SF3B1 modulators inhibited PDAC cell proliferation and prompted induction of cell death.All compounds showed an interesting anti-migratory ability,associated with splicing RON/ΔRON shift in SUIT-2 cells after 24 h exposure.Moreover,IS1 and IS4 potentiated the sensitivity to gemcitabine in both conventional 2D monolayer and 3D spheroid cultures,and these results might be explained by the statistically significant increase in hENT1 expression(P<0.05 vs.untreated control cells),potentially reversing PDAC chemoresistance.Conclusion:These results support further studies on new SF3B1 inhibitors and the role of RON/hENT1 modulation to develop effective drug combinations against PDAC.展开更多
文摘目的:分析胃癌石蜡组织BRCA1、hENT1、Topo1 mRNA水平与新鲜胃癌组织多西紫杉醇、吉西他滨、伊立替康体外药物敏感性的关系。方法:收集36例经病理确诊的新鲜胃癌标本,采用三维微组织块培养法(HDRA)行三种药物的体外药物敏感试验。实时荧光定量PCR检测对应胃癌石蜡组织中BRCA1、hENT1、To-po1 mRNA水平。结果:新鲜胃癌组织对三种药物的敏感性均与临床特征无明显相关性。对应胃癌石蜡组织中BRCA1、hENT1、Topo1 mRNA水平与临床特征无明显相关性。在胃癌组织中,hENT1 mRNA水平最高,BRCA1 mRNA水平最低。胃癌石蜡组织BRCA1 mRNA水平与新鲜胃癌组织的多西紫杉醇敏感性正相关(7.927 vs 3.464,P=0.001);hENT1 mRNA水平在吉西他滨敏感组高于耐药组(15.710 vs 10.145,P=0.243),Topo1 mRNA水平在伊立替康敏感组高于耐药组(10.024 vs 6.038,P=0.124),但均未达统计学差异。结论:胃癌石蜡组织BRCA1mRNA水平与新鲜胃癌组织对多西紫杉醇的敏感性呈正相关。
文摘High human equilibrative nucleoside transporter 1(hENT1)-expression has shown a survival benefit in pancreatic cancer patients treated with gemcitabine in several studies.The aim of this systematic review was to summarize the results and try to assess the predictive value of hENT1 for determining gemcitabine outcome in pancreatic cancer.Relevant articles were obtained from PubMed,Embase and Cochrane databases.Studies evaluating hENT1-expression in pancreatic tumor cells from patients treated with gemcitabine were selected.Outcome measures were overall survival,disease-free survival(DFS),toxicity and response rate.The database searches identified 10 studies that met the eligibility criteria,and a total of 855 patients were included.Nine of 10 studies showed a statistically significant longer overall survival in univariate analyses in patients with high hENT1-expression compared to those with low expression.In the 7 studies that reported DFS as an outcome measure,6 had statistically longer DFS in the high hENT1 groups.Both toxicity and response rate were reported in only 2 articles and it was therefore hard to draw any major conclusions.This review provides evidence that hENT1 is a predictive marker for pancreatic cancer patients treated with gemcitabine.Some limitations of the review have to be taken into consideration,the majority of the included studies had a retrospective design,and there was no standardized scoring protocol for hENT1-expression.
文摘目的探讨hENT1在生发中心B细胞(germinal center B cell-like,GCB)型与非GCB(non-GCB)型弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)中的表达及意义。方法采用免疫组化PV 6000两步法检测CD10、BCL-6、MUM1蛋白在DLBCL的表达并对DLBCL进行亚型分类,同时检测hENT1蛋白的表达,探讨免疫组化染色结果和临床病理参数及预后的关系。结果 (1)hENT1蛋白在DLBCL的GCB及non-GCB亚型中表达差异有显著性(P=0.031,P<0.05)。(2)hENT1的表达与患者性别、年龄、部位、LDH高低、Ann Arbor分期、有无B症状的差异均无统计学意义。(3)对76例DLBCL患者进行生存分析,中位随访时间21个月。Log-rank检验GCB/non-GCB组累计生存率差异有统计学意义(P=0.010)。结论 DLBCL中non-GCB型患者比例较大,预后差。在治疗过程中,检测hENT1的表达为能否使用核苷类药物提供依据。
基金It is supported by Major Project of Science and Technology of Beijing(D0905001040731)
文摘Objective:To investigate the expression of hENT1 and ERCCl genes in tumor tissues non-small cell lung cancer(NSCLC).Methods:Fresh non-small lung cancer specimens were transplanted into nude mice.Twenty mice were randomized into two groups:experimental group receiving gemeitabine plus cisplatin and control group receiving 0.9%physiological saline.The expressions of hENTi and ERCC1 mRNA in tumor tissue were detccted by real-time fluorescent quantitative PCR.The volume of tumor,the weight of nude mice and tumor volume were respectively measured and calculated 2-3 times per week.Tissue samples were collected from NSCLC mice treated with gemeitabine plus carboplatin.Results:The histological examination showed that many tumor cells were well preserved in nude mice.The rate of transplanted tumor cells was 86.7%.The concomitant treatment study showed that the rate of TV,RTV,T/C in GEM + DDP group was the lowest.LBP + DOC,DDP + DOC obviously influenced the body weight.Compared with NS group,DDP group,GEM group,the survival period and the level of hENTl of DDP+GEM group increased obviously,the level of ERCC1 decreased significantly(P【0.05).Conclusions:The expression of hENT1 and ERCC1 genes in tumor tissues were closely correlated with the response to chemotherapy and prognosis of patients with NSCLC treated with gemeitabine plus cisplatin.
基金funded by grants from the National Natural Science Foundation of China(81872791 and 21372050)the Young Elite Scientists Sponsorship Program by the China Association forScience and Technology(2017QNRC061)+1 种基金National Key R&D Program of China(2017YFA0506000)the Key Research and Development Program of Ningxia(2019BFG02017 and 2018BFH02001,China)
文摘Human immunodeficiency virus(HIV)is the primary infectious agent of acquired immunodeficiency syndrome(AIDS),and non-nucleoside reverse transcriptase inhibitors(NNRTIs)are the cornerstone of HIV treatment.In the last 20 years,our medicinal chemistry group has made great strides in developing several distinct novel NNRTIs,including 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine(HEPT),thio-dihydro-alkoxy-benzyl-oxopyrimidine(S-DABO),diaryltriazine(DATA),diarylpyrimidine(DAPY)analogues,and their hybrid derivatives.Application of integrated modern medicinal strategies,including structure-based drug design,fragment-based optimization,scaffold/fragment hopping,molecular/fragment hybridization,and bioisosterism,led to the development of several highly potent analogues for further evaluations.In this paper,we review the development of NNRTIs in the last two decades using the above optimization strategies,including their structure-activity relationships,molecular modeling,and their binding modes with HIV-1 reverse transcriptase(RT).Future directions and perspectives on the design and associated challenges are also discussed.
文摘Equilibrative nucleoside transporters （ENTs）, which facilitate cross-membrane transport of nucleosides and nucleoside-derived drugs, play an important role in the salvage pathways of nucleotide synthesis, cancer chemotherapy, and treatment for virus infections. Functional characterization of ENTs at the molecular level remains technically challenging and hence scant. In this study, we report successful purification and bio- chemical characterization of human equilibrative nucle- oside transporter 1 （hENT1） in vitro. The HEK293F- derived, recombinant hENT1 is homogenous and func- tionally active in proteoliposome-based counter flow assays, hENT1 transports the substrate adenosine with a Km of 215 ＋ 34 pmol/L and a Vmax of 578 ＋ 23.4 nmol mg-1 min-1. Adenosine uptake by hENT1 is competi- tively inhibited by nitrobenzylmercaptopurine ribonu- cleoside （NBMPR）, nucleosides, deoxynucleosides, and nucleoside-derived anti-cancer and anti-viral drugs. Binding of hENT1 to adenosine, deoxyadenosine, and adenine by isothermal titration calorimetry is in general agreement with results of the competitive inhibition assays. These results validate hENT1 as a bona fide target for potential drug target and serve as a useful basis for future biophysical and structural studies.
基金This work was supported by Cancer Center Amsterdam(CCA)Foundation grants 2015 and 2018Italian Association for Cancer Research(AIRC)IG grant to Giovannetti E,European Union 2014-2020 PON Ricerca e Innovazione grant from the Italian Ministry of Education,University and Research,entitled“PROGEMA-Processi Green per l’Estrazione di Principi Attivi e la Depurazione di Matrici di Scarto e Non”(ARS01_00432)to Diana P.
文摘Aim:Because mutations of splicing factor 3B subunit-1(SF3B1)have been identified in 4%of pancreatic ductal adenocarcinoma(PDAC)patients,we investigated the activity of new potential inhibitors of SF3B1 in combination with gemcitabine,one of the standard drugs,in PDAC cell lines.Methods:One imidazo[2,1-b][1,3,4]thiadiazole derivative(IS1)and three indole derivatives(IS2,IS3 and IS4),selected by virtual screening from an in-house library,were evaluated by the sulforhodamine-B and wound healing assay for their cytotoxic and antimigratory activity in the PDAC cells SUIT-2,Hs766t and Panc05.04,the latter harbouring the SF3B1 mutations.The effects on the splicing pattern of proto-oncogene recepteur d’origine nantais(RON)and the gemcitabine transporter human equilibrative nucleoside transporter-1(hENT1)were assessed by PCR,while the ability to reduce tumour volume was tested in spheroids of primary PDAC cells.Results:The potential SF3B1 modulators inhibited PDAC cell proliferation and prompted induction of cell death.All compounds showed an interesting anti-migratory ability,associated with splicing RON/ΔRON shift in SUIT-2 cells after 24 h exposure.Moreover,IS1 and IS4 potentiated the sensitivity to gemcitabine in both conventional 2D monolayer and 3D spheroid cultures,and these results might be explained by the statistically significant increase in hENT1 expression(P<0.05 vs.untreated control cells),potentially reversing PDAC chemoresistance.Conclusion:These results support further studies on new SF3B1 inhibitors and the role of RON/hENT1 modulation to develop effective drug combinations against PDAC.
